Skip Navigation

This Article
Right arrow Full Text Freely available
Right arrow FREE Full Text (PDF) Freely available
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in ISI Web of Science
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Add to My Personal Archive
Right arrow Download to citation manager
Right arrow Search for citing articles in:
ISI Web of Science (12)
Right arrowRequest Permissions
Right arrow Disclaimer
Google Scholar
Right arrow Articles by Seaton, R.A.
Right arrow Articles by Nathwani, D.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Seaton, R.A.
Right arrow Articles by Nathwani, D.
Social Bookmarking
Add to CiteULike   Add to Connotea   Add to Del.icio.us  
What's this?

Q J Med 1999; 92: 659-667
© 1999 Association of Physicians

Out-patient parenteral antimicrobial therapy–a viable option for the management of cutaneous leishmaniasis

R.A. Seaton, J. Morrison, I. Man1, J. Watson2 and D. Nathwani

From the Infection and Immunodeficiency Unit, and 1 Department of Dermatology, Tayside University Hospitals NHS Trust, and 2 Department of Clinical Parasitology, Hospital for Tropical Diseases, London, UK

Received 7 June 1999 and in revised form 25 August 1999

Dr R.A. Seaton, Directorate of Medicine, Tayside University Hospitals NHS Trust, Ninewells Hospital, Dundee DD1 9SY. e-mail: aseaton66{at}aol.com

Cutaneous infection with Leishmania braziliensis complex requires treatment with parenteral pentavalent antimonials to prevent development of mucocutaneous leishmaniasis. Patients with imported disease are usually managed in hospital because of concerns over drug toxicity. This study describes the clinical features and outcome of infection treated in the UK in an out-patient setting. Thirteen marines (aged 19–35 years) who acquired leishmaniasis in Belize were studied prospectively. Three had at least two lesions (0.6–3 cm diameter), eight had regional lymphadenopathy and one had localized painless lymphatic thickening. Histology for amastigotes and PCR for Leishmania braziliensis complex was positive in all. Culture was positive in six. Patients received 1.5–2 g (mean 1.7 g) (20 mg/kg) sodium stibogluconate intravenously daily for 20 days. All developed transient musculoskeletal symptoms and asymptomatic hepatitis. Eleven developed biochemical pancreatitis, and one thrombocytopenia. Three developed transient ECG changes and one herpes zoster. There were four device-related infections, two requiring hospitalization (one required surgical drainage of an abscess). All lesions re-epithelialized. A total of 250 bed-days were saved over a 67-day period. These results indicate that in selected patients, out-patient therapy for cutaneous leishmaniasis with parenteral high-dose sodium stibogluconate may be appropriate, provided there is adequate monitoring of therapy.


Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us    What's this?


This article has been cited by other articles:


Home page
 J Antimicrob ChemotherHome page
J. Blum, P. Desjeux, E. Schwartz, B. Beck, and C. Hatz
Treatment of cutaneous leishmaniasis among travellers
J. Antimicrob. Chemother., February 1, 2004; 53(2): 158 - 166.
[Abstract] [Full Text] [PDF]

Home page
 QJMHome page
D.K. Kochar, S. Aseri, B.V. Sharma, R.A. Bumb, R.D. Mehta, and S.K. Purohit
The role of rifampicin in the management of cutaneous leishmaniasis
QJM, November 1, 2000; 93(11): 733 - 737.
[Abstract] [Full Text] [PDF]


Disclaimer:
Please note that abstracts for content published before 1996 were created through digital scanning and may therefore not exactly replicate the text of the original print issues. All efforts have been made to ensure accuracy, but the Publisher will not be held responsible for any remaining inaccuracies. If you require any further clarification, please contact our Customer Services Department.